Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2018 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.
Mesguich C, Cazeau AL, Bouabdallah K, HindiƩ E. Mesguich C, et al. Br J Haematol. 2018 Apr;181(1):124-125. doi: 10.1111/bjh.14494. Epub 2017 Jan 20. Br J Haematol. 2018. PMID: 28106255 No abstract available.
Role of 18F-FDG PET/CT in Posttreatment Evaluation of Anal Carcinoma.
Houard C, Pinaquy JB, Mesguich C, Henriques de Figueiredo B, Cazeau AL, Allard JB, Laharie H, Bordenave L, Fernandez P, Vendrely V. Houard C, et al. Among authors: mesguich c. J Nucl Med. 2017 Sep;58(9):1414-1420. doi: 10.2967/jnumed.116.185280. Epub 2017 Mar 9. J Nucl Med. 2017. PMID: 28280225 Free article.
Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, Bordenave L, HindiƩ E. Mesguich C, et al. Br J Haematol. 2016 Nov;175(4):652-660. doi: 10.1111/bjh.14292. Epub 2016 Aug 19. Br J Haematol. 2016. PMID: 27539369
Feedback